Coulter Pharma, SmithKline Beecham deal

SB returned to CLTR development and commercialization rights outside the U.S. to CLTR's Bexxar radioimmunotherapy to treat

Read the full 176 word article

How to gain access

Continue reading with a
two-week free trial.